Pathwork Diagnostics, a maker of genomics-based oncology diagnostics, has appointed Lee R. McCracken CEO, effective Oct. 10. He replaces Deborah J. Ness, who left the firm to pursue other opportunities. McCracken, who most recently served as corporate head of business development at Prometheus Laboratories, hopes to make Pathwork's Tissue of Origin test "the standard of care for difficult-to-diagnose cancer tumors," he said in a Nov. 5 press release. The molecular diagnostic for determining a patient’s type of cancer was 510(k)-cleared in 2008 and is covered by Medicare. (See Also see "Diagnostics In Brief" - Medtech Insight, 4 August, 2008..)
Lee R. McCracken, CEO, Pathwork Diagnostics
